| Literature DB >> 30829072 |
Niloofar Farzad1,2, Nastaran Barati1,3,2, Amir Abbas Momtazi-Borojeni4, Mona Yazdani1, Atefeh Arab1,3,2, Atefeh Razazan5, Sheida Shariat1, Mercedeh Mansourian1,2, Azam Abbasi1, Zahra Saberi1, Ali Badiee1,3,2, Seyed Amir Jalali6, Mahmoud Reza Jaafari1,3,2.
Abstract
The present study was aimed to develop an effective nanoliposomal vaccine delivery system with P435 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. The nanoliposome formulation composed of DSPC/DSPG/Chol/DOPE and monophosphoryl lipid A was used as an adjuvant. Liposomal formulations were prepared and their physical properties were characterized. Anti-tumoral efficacy of formulations was evaluated by immunization of tumor-bearing BALB/c mice and the generated immune response was studied by using ELISpot and flow cytometry analysis. The results of the study demonstrated Lip + DOPE + P535 formulation caused the lowest tumor size and the longest survival time in TUBO mice model and could make it a promising candidate in developing effective vaccines against HER2-positive breast cancers.Entities:
Keywords: HER2/neu protein; P435 peptide; Peptide-conjugated nanoliposomes; breast cancer; cytotoxic T-cell response; prophylactic vaccine
Mesh：
Substances：
Year: 2019 PMID： 30829072 DOI： 10.1080/21691401.2019.1576702
Source DB: PubMed Journal: Artif Cells Nanomed Biotechnol ISSN： 2169-1401 Impact factor: 5.678